Chronic Graft-Versus-Host Disease (cGVHD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Chronic Graft-Versus-Host Disease (cGVHD) lasts more than three months after transplantation and is the most common late complication of allogeneic HSCT, accounting for approximately 25% of pediatric patients. Chronic GVHD is the primary cause of nonrelapse mortality and morbidity in long-term HSCT survivors. cGVHD typically manifests with multiorgan pathology and historically has been defined temporally as GVHD that occurred later than 100 days post-SCT. Chronic GVHD has a wide prevalence ranging from 6% to 80%, depending on donor type, recipient age, and the source of the transplanted hemopoietic cells. Chronic GVHD is diagnosed by distinguishing it from acute GVHD, having at least one diagnostic clinical sign of chronic GVHD, or having at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests in the same or another organ, and ruling out other possible diagnoses. Chronic GVHD symptoms can appear in the skin, oral and gut mucosa, eyes, lungs, female genitalia, and connective tissue.

 

The incidence of Chronic Graft-Versus-Host Disease (cGVHD) ranges from 14 to 16 cases per million in the USA.

 

The competitive landscape of Chronic Graft-Versus-Host Disease (cGVHD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic Graft-Versus-Host Disease (cGVHD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Graft-Versus-Host Disease (cGVHD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic Graft-Versus-Host Disease (cGVHD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Ibrutinib and Rituximab  Pharmacyclics LLC.       Phase 2

2          Ruxolitinib         Incyte Corporation         Phase 2

3          Axatilimab         Syndax Pharmaceuticals            Phase 2

4          SCM-CGH        SCM Lifescience Co., LTD.        Phase 2

5          Belumosudil      Kadmon Corporation, LLC         Phase 2

6          Interleukin-2      Prometheus Laboratories           Phase 2

7          R348 Ophthalmic Solution          Rigel Pharmaceuticals   Phase 2

8          TQ05105 Tablet            Chia Tai Tianqing Pharmaceutical             Phase 2

9          Efavaleukin Alfa Amgen  Phase 2

10        Budesonide       Dr. Falk Pharma GmbH Phase 3

Continued